Browse Category

NYSE:EAT News 11 December 2025 - 2 January 2026

Chili’s jabs at McDonald’s ‘value meals’ with $10.99 deal as diners watch prices

Chili’s jabs at McDonald’s ‘value meals’ with $10.99 deal as diners watch prices

Chili’s Grill & Bar promoted a $10.99 burger meal on X this week, criticizing fast-food value bundles as lacking real value. The campaign comes as restaurant brands compete for price-sensitive diners. Chili’s parent Brinker International has gained ground with lower-income customers, according to Reuters. Separately, Chili’s closed its Orlando airport location after 22 years, airport officials said.
2 January 2026
Brinker International (EAT) Stock: Fresh News, Analyst Forecasts and Turnaround Outlook as of December 11, 2025

Brinker International (EAT) Stock: Fresh News, Analyst Forecasts and Turnaround Outlook as of December 11, 2025

Brinker International, Inc. (NYSE: EAT) — the parent of Chili’s Grill & Bar and Maggiano’s Little Italy — is back in the market spotlight. On December 11, 2025, Brinker shares are trading around $146, up roughly 7% intraday, after bouncing between $135.85 and $146.00 so far in today’s session. That puts the stock about 24% below its 52‑week high near $192 and roughly 46% above its 52‑week low around $100, underscoring how volatile the turnaround story has been for investors over the past year. Investing.com+1 Company snapshot: a Chili’s‑powered turnaround Brinker operates more than 1,600 restaurants worldwide under the Chili’s

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop